Rocket Pharmaceuticals (RCKT) counsel sells small stake to cover RSU taxes
Rocket Pharmaceuticals General Counsel Martin Wilson sold 662 shares of company common stock for $3.014 per share on May 19, 2026. This sale was made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and represents a small portion of his total holdings. After the transaction, Mr. Wilson still beneficially owns 677,977 shares.
Rocket Pharmaceuticals (RCKT) officer sells 384 shares to cover RSU tax withholding
John Militello, an officer at Rocket Pharmaceuticals (RCKT), sold 384 shares of common stock for $3.014 per share on May 19, 2026. This sale was conducted to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs), not as a discretionary portfolio adjustment. After the transaction, Militello directly holds 89,780 shares of RCKT common stock.
Rocket Pharmaceuticals (RCKT) CEO logs small stock sale to cover RSU tax obligations
Rocket Pharmaceuticals (RCKT) CEO Gaurav Shah sold 2,409 shares of common stock for approximately $3.014 per share. This sale, totaling $7,261, was primarily to cover tax withholding obligations related to the vesting of his Restricted Stock Units (RSUs) and is considered a routine, compensation-driven transaction. Following this sale, Shah directly holds 1,040,918 shares, with additional indirect holdings.
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
Rocket Pharmaceuticals (RCKT) recently held its 2026 Annual Meeting of Stockholders, where shareholders re-elected the full slate of seven directors and ratified EisnerAmper LLP as the independent registered accounting firm. Investors also approved executive compensation and a stock option exchange program, signaling support for governance continuity and talent retention. While TipRanks' AI Analyst "Spark" rates RCKT as Neutral due to weak financials, the company benefits from strong corporate catalysts like FDA accelerated approval and significant non-dilutive funding.
Rocket Pharmaceuticals shareholders approve board nominees and proposals at annual meeting
Rocket Pharmaceuticals (NASDAQ: RCKT) held its 2026 Annual Meeting of Stockholders where shareholders approved the election of seven directors, ratified EisnerAmper LLP as the independent registered accounting firm, approved executive compensation, and authorized a stock option exchange program. These decisions follow recent company developments including the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million and the FDA's accelerated approval of Kresladi, extending the company’s cash runway. Analysts from Leerink Partners and BofA Securities have adjusted their price targets for Rocket Pharmaceuticals upwards due to these events.
Rocket Pharmaceuticals (RCKT) investors approve directors, pay and option exchange
Rocket Pharmaceuticals (RCKT) held its 2026 Annual Meeting of Stockholders, where investors approved the election of all seven nominated directors, ratified EisnerAmper LLP as the independent registered accounting firm, and endorsed the compensation of named executive officers on a non-binding advisory basis. Additionally, stockholders approved a stock option exchange program. These decisions reflect significant shareholder participation, with approximately 74.02% of eligible shares present.
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
Leerink Partners recently boosted its price target for Rocket Pharmaceuticals (RCKT) to $12, maintaining a Market Perform rating after the company sold FDA priority review vouchers for $180 million. This non-dilutive capital extends Rocket's cash runway into Q2 2028, easing balance sheet concerns and strengthening its gene therapy pipeline advancement. While the Street expects a significant stock surge, the article also promotes a separate AI stock opportunity with higher return potential.
662-Share Rule 144 Notice for RCKT (NASDAQ: RCKT)
Rocket Pharmaceuticals, Inc. (RCKT) filed a Rule 144 notice disclosing the registration for sale of 662 shares of Common Stock, arising from Restricted Stock Vesting on May 15, 2026. The filing also noted a separate prior sale of 3,361 shares on May 13, 2026, which generated proceeds of $12,118.42. Fidelity Brokerage Services LLC is listed as the broker for these transactions.
Director resale notice — RCKT (NASDAQ: RCKT) lists 384 shares from vesting
Rocket Pharmaceuticals, Inc. (RCKT) filed a Form 144 notice indicating a proposed sale of 384 common shares related to a restricted stock vesting event on May 15, 2026. The filing also noted a prior sale of 855 shares on May 13, 2026. This activity represents routine insider share liquidation, primarily for tax purposes or diversification, and is generally considered neutral in impact according to the analysis.
Proposed resale of 2,409 Common shares by RCKT filer (Form 144)
A Form 144 filing indicates a proposed resale of 2,409 common shares of Rocket Pharmaceuticals, Inc. (RCKT) linked to a Restricted Stock Vesting event on May 15, 2026. The filing also notes 2,728 common shares were sold in the prior three months on May 13, 2026, by Gaurav Shah. This procedural SEC notice announces a planned resale under safe-harbor rules, with transaction details to follow upon sale.
5 Best Gene Therapy Stocks to Buy in 2026
This article identifies Rocket Pharmaceuticals Inc (NASDAQ: RCKT) as one of the top five gene therapy stocks to consider buying in 2026. The company is projected to see a significant stock increase, partly due to its recent sale of FDA priority review vouchers, which extended its cash runway to fund clinical programs. Rocket Pharmaceuticals focuses on developing gene therapies for rare diseases, with programs in cardiovascular, immunology, and hematology conditions.
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
Rocket Pharmaceuticals (RCKT) reported a Q1 2026 net loss of $47.6 million, or $0.42 per share, with decreased R&D and G&A expenses due to realignment. The company extended its operational runway into Q2 2028 after monetizing a Priority Review Voucher for $180 million, following FDA approval for KRESLADI. Rocket also has ongoing clinical pipeline developments, including reinitiating a Phase 2 trial for Danon disease and planning for trials in arrhythmogenic cardiomyopathy and BAG3-dilated cardiomyopathy.
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock By Investing.com
Rocket Pharmaceuticals (NASDAQ: RCKT) Vice President John Militello sold 855 shares of company stock for a total of $3,083. The sale, executed on May 13, 2026, at $3.606 per share, was to cover tax obligations from vested restricted stock units. Despite the stock trading down from its 52-week high, recent developments like the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million and FDA approval of KRESLADI have led analysts to raise price targets for the company.
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock
John Militello, VP of Finance at Rocket Pharmaceuticals (NASDAQ: RCKT), sold 855 shares worth $3,083 to cover tax obligations from restricted stock unit vesting. Following the sale, Militello still directly holds over 90,000 shares. The company recently increased its cash runway by selling a Priority Review Voucher for $180 million and received FDA approval for KRESLADI, a gene therapy.
Rocket Pharma general counsel Wilson sells $12,119 in stock
Martin Wilson, General Counsel at ROCKET PHARMACEUTICALS, INC. (NASDAQ:RCKT), sold 3,361 shares worth $12,119 to cover tax obligations from vested restricted stock units. Following the sale, Wilson holds 678,639 shares in the company. Rocket Pharmaceuticals recently sold its Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway and leading to increased price targets from several analyst firms.
Rocket Pharma general counsel Wilson sells $12,119 in stock By Investing.com
Rocket Pharmaceuticals General Counsel Martin Wilson sold 3,361 shares of the company's stock for $12,119 to cover tax obligations from RSU vesting. Following the sale, Wilson directly holds 678,639 shares. The stock is considered undervalued by InvestingPro, and the company recently extended its cash runway by selling a Priority Review Voucher for $180 million after FDA approval of its gene therapy, Kresladi.
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax withholding
Rocket Pharmaceuticals (RCKT) General Counsel Martin Wilson sold 3,361 shares of common stock at $3.606 per share. The sale was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs), not as a discretionary portfolio change. Post-transaction, Wilson still directly holds 678,639 shares, with additional holdings in RSUs.
Rocket Pharma (RCKT) CEO sells shares to cover RSU tax obligations
Rocket Pharmaceuticals (RCKT) CEO Gaurav Shah sold 2,728 shares of common stock on May 13, 2026, for $3.606 per share. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following the transaction, Shah directly holds 1,043,327 shares, with additional indirect holdings through a trust and his spouse.
Rocket Pharmaceuticals (RCKT) insider sells 855 shares for tax withholding
Rocket Pharmaceuticals (RCKT) officer John Militello sold 855 shares of common stock at $3.606 per share. This transaction was an open-market sale to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). After the sale, Militello directly holds 90,164 shares, including RSUs, indicating this was a tax-related disposition rather than a discretionary sale.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Analysts
Rocket Pharmaceuticals (RCKT) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $11.54. Recent analyst actions include Goldman Sachs cutting its rating to "sell" with a $3 target, while others maintained more bullish outlooks. The company reported a Q1 EPS loss of $0.42, slightly missing estimates, and is facing scrutiny over the launch of its Kresladi product, insider selling, and weakened earnings estimates.
RCKT (NASDAQ) Rule 144: Director sales listed; 3,361 vested shares
Rocket Pharmaceuticals, Inc. (RCKT) has filed a Rule 144 notice for 3,361 shares of Common Stock related to a restricted stock vesting event on May 11, 2026. This filing also discloses previous sales by Martin Wilson, totaling 13,629 shares in February 2026 for a combined value of $45,176.94. The transaction is identified as a routine transfer tied to compensation.
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing
Rocket Pharmaceuticals (RCKT) has filed a Form 144, indicating proposed sales related to recent restricted stock vesting. The filing details a restricted stock vesting entry for 2,728 shares on May 11, 2026, and also lists prior dispositions by an individual in February 2026. This SEC filing has been assessed as having a neutral impact and sentiment.
RCKT (NASDAQ: RCKT) files Form 144 for 855 vested shares
Rocket Pharmaceuticals (NASDAQ: RCKT) has filed a Form 144, indicating a proposed sale of 855 shares of common stock stemming from restricted stock vesting on May 11, 2026. This routine SEC filing provides notice of an intended resale and includes details of prior sales by the same individual in February 2026. The filing has a neutral impact and sentiment, serving primarily as an administrative disclosure.
Rocket Pharmaceuticals (RCKT) insider sale covers RSU tax obligations
Rocket Pharmaceuticals (RCKT) insider Sarbani Chaudhuri sold 17,650 shares of common stock at $3.838 per share on May 7, 2026. The sale was specifically to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri retains 267,510 shares, which includes RSUs convertible to common stock.
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock
Rocket Pharmaceuticals' Chief Commercial & Medical Affairs Officer, Sarbani Chaudhuri, sold 17,650 shares worth approximately $67,740 to cover tax obligations from vested restricted stock units. Despite the stock’s 49% decline over the past year, InvestingPro suggests it might be undervalued, noting the company holds more cash than debt but is not yet profitable. Recent positive developments include the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million and FDA accelerated approval for KRESLADI, leading to raised price targets from Leerink Partners and BofA Securities.
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals (RCKT) shares fell after reporting a wider-than-expected loss in Q1 2026, though general and administrative and R&D expenses decreased due to disciplined spending. The company, which did not record any revenues, recently received FDA accelerated approval for its gene therapy Kresladi and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million, which will fund operations and its cardiovascular pipeline into Q2 2028. RCKT also provided updates on its investigational gene therapies RP-A501 for Danon disease and new candidates for other cardiomyopathies.
RCKT Maintained by Chardan Capital -- Price Target Remains $11
Chardan Capital has maintained a Buy rating for Rocket Pharmaceuticals (RCKT) with an unchanged price target of $11.00, despite the company's current stock price of $3.63 and a low GF Score™ of 32/100. This rating suggests a belief in significant upside potential, contrasting with financial challenges like low profitability and lack of GF Value™ data, as well as recent insider selling activity of $122,000. Investors are advised to consider both the optimistic analyst outlook and the company's financial weaknesses.
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US), maintaining a target price of $10. This indicates a continued positive outlook on the company's stock performance from CCORF analysts.
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
Rocket Pharmaceuticals (RCKT) plans to provide updates on its cardiac gene therapy programs in the second half of 2026, which Wedbush analysts believe will act as strong stock catalysts. The updates will cover the Phase 1 Danon disease program and the Phase 2 Pompe disease program, with initial data from the expanded cohort of the Danon study expected. Wedbush maintains an "Outperform" rating and a $66 price target for RCKT.
Rocket Pharmaceuticals targets innovation in rare cardiovascular gene therapy at ASGCT event
Rocket Pharmaceuticals is set to participate in the ASGCT Annual Meeting to discuss advancements in gene therapy for rare cardiovascular diseases. The company aims to collaborate with experts and showcase new approaches to treating these complex conditions. This participation highlights Rocket Pharmaceuticals' ongoing commitment to innovation and research in genetic medicine.
Rocket Pharmaceuticals Reports Q1 2026 Results: KRESLADI FDA Approval, $180M PRV Sale, and Cash Runway to 2028
Rocket Pharmaceuticals (NASDAQ: RCKT) announced strong Q1 2026 results, highlighted by the FDA accelerated approval of KRESLADI™ for severe LAD-I and the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million. These achievements extend the company's cash runway into Q2 2028 and validate its gene therapy pipeline, which includes advancements in treatments for Danon Disease, BAG3-related Dilated Cardiomyopathy, and PKP2 Arrhythmogenic Cardiomyopathy. The company also reported reduced R&D and G&A expenses, leading to a decreased net loss.
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $16
Wedbush has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained its price target of $16. This indicates continued confidence from the firm in the company's prospects.
Rocket Pharmaceuticals: Q1 Earnings Snapshot
Rocket Pharmaceuticals Inc. (RCKT) reported a first-quarter loss of $47.6 million, or 42 cents per share, which missed Wall Street expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 41 cents per share. This financial update was generated by Automated Insights using Zacks Investment Research data.
Rocket Pharmaceuticals reports Q1 2026 net loss $47.6M, cash $144.4M and PRV sale extends runway
Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million and held $144.4 million in cash. The company also announced the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million, which, combined with existing cash, is expected to extend its operational runway into Q2 2028. Key business highlights included reinitiating a pivotal Phase 2 trial for Danon disease, anticipating first patient dosing for RP-A701 in mid-2026, and ongoing engagement with the FDA for RP-A601.
Rocket Pharma (NASDAQ: RCKT) wins first approval, plans $180M PRV sale
Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million with no revenue, while its research and development and general and administrative expenses decreased year-over-year. The company recently received FDA accelerated approval for KRESLADI™ for severe LAD-I and plans to sell the related Priority Review Voucher for $180 million, which is expected to provide non-dilutive funding and extend its operating runway. Rocket faces ongoing class action and derivative litigation related to its Danon disease program.
Rocket Pharmaceuticals (NASDAQ: RCKT) wins KRESLADI nod, sells $180M PRV
Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a gene therapy for severe LAD-I, and subsequently sold its Rare Pediatric Disease Priority Review Voucher for $180 million. This non-dilutive financing, combined with a narrowing net loss for Q1 2026, extends Rocket's operational cash runway into the second quarter of 2028. The company also provided updates on its cardiovascular gene therapy pipeline and reported a Q1 2026 net loss of $47.6 million, an improvement from $61.3 million a year prior.
Rocket Pharmaceuticals: Q1 Earnings Snapshot
Rocket Pharmaceuticals Inc. reported a first-quarter loss of $47.6 million, or 42 cents per share, which was below Wall Street's expectations of a 41-cent loss per share. The financial data was sourced from Zacks Investment Research.
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing
This article details an SEC Form 144 filing by ROCKET PHARMACEUTICALS, INC. (RCKT) on May 7, 2026, concerning a proposed sale of 17,650 shares of common stock with an aggregate market value of $67,740.70. The shares were acquired through restricted stock vesting as compensation on May 5, 2026. The filing indicates a "Neutral" impact and sentiment.
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals announced its first-quarter 2026 financial results, highlighting ongoing progress in its cardiovascular gene therapy pipeline and regulatory interactions. The company reported a net loss of $67.5 million for the quarter and expects its current cash resources, combined with proceeds from a Priority Review Voucher sale, to fund operations into the second quarter of 2028. Key clinical developments include progress in the Phase 2 study of RP-A501 for Danon Disease and engagement with the FDA regarding RP-A501 for PKP2-ACM, and RP-A506 for BAG3-DCM.
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals reported its first-quarter 2026 financial results, highlighting progress in its gene therapy pipeline, including reinitiating dosing for the pivotal Phase 2 trial of RP-A501 for Danon disease. The company also announced the FDA accelerated approval of KRESLADI™ for severe LAD-I and the subsequent monetization of its Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway into the second quarter of 2028. Financial results showed a net loss of $47.6 million, an improvement from the previous year, driven by reduced R&D and G&A expenses.
Rocket Pharmaceuticals: Q1 Earnings Snapshot
Rocket Pharmaceuticals Inc. reported a first-quarter loss of $47.6 million, or 42 cents per share, falling short of Wall Street expectations of a 41-cent loss per share. This financial snapshot was generated using data from Zacks Investment Research.
Number of shareholders of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT
This article displays the number of shareholders for Rocket Pharmaceuticals, Inc. (RCKT) on the NASDAQ stock market. It is part of a financial data overview available on TradingView, providing basic company information and market details. The core content is a table showing the period, value, change, and change percentage for the number of shareholders.
Rocket Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Rocket Pharmaceuticals Inc (RCKT) is projected to report a loss of 41 cents per share. This information comes from a Refinitiv earnings preview.
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $9
BofA Securities has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained its price target of $9. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Rocket Pharmaceuticals has announced a $180 million sale of its Rare Pediatric Disease Priority Review Voucher (PRV), which was awarded following the FDA approval of KRESLADI. This non-dilutive capital extends Rocket's cash runway into Q2 2028, enabling continued advancement of its cardiovascular gene therapy pipeline. The sale highlights the ongoing strategic value of PRVs in incentivizing the development of treatments for rare pediatric conditions.
Rocket Pharmaceuticals sells priority review voucher for $180M By Investing.com
Rocket Pharmaceuticals (NASDAQ: RCKT) has sold its Rare Pediatric Disease Priority Review Voucher for $180 million, a move that extends its cash runway into the second quarter of 2028. This voucher was granted after the FDA approved KRESLADI (marnetegragene autotemcel). The proceeds will fund the company's cardiovascular gene therapy pipeline.
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $12
LifeSci Capital has reiterated its Buy rating on Rocket Pharmaceuticals (RCKT.US) and maintained its price target of $12. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Rocket Pharmaceuticals sells priority review voucher for $180M
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) has sold its Rare Pediatric Disease Priority Review Voucher for $180 million, significantly extending its cash runway into Q2 2028. This move follows the FDA's accelerated approval of KRESLADI and will fund its cardiovascular gene therapy pipeline. Analysts maintain positive outlooks, with several firms raising their price targets for RCKT.
Rocket Pharmaceuticals sells priority review voucher for $180 million
Rocket Pharmaceuticals (RCKT) has announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million, following the FDA's accelerated approval of KRESLADI. The company plans to use these non-dilutive funds to support its cardiovascular gene therapy pipeline and extend its cash runway into the second quarter of 2028. This move provides significant capital to advance treatments for rare cardiovascular diseases.
$180M PRV sale extends Rocket Pharmaceuticals (RCKT) cash runway to 2028
Rocket Pharmaceuticals (RCKT) has sold its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in cash. This non-dilutive capital extends the company's cash runway into the second quarter of 2028, enabling continued advancement of its cardiovascular gene therapy pipeline. The PRV was granted following the FDA's accelerated approval of KRESLADI™, Rocket's gene therapy for severe LAD-I.
